SNM’s Clinical Trials Network has expanded to include relationships with European PET radiopharmaceutical manufacturing sites to support molecular and nuclear imaging facilities on the continent that are gearing up to perform scientific studies for the program.
SNM's Clinical Trials Network has expanded to include relationships with European PET radiopharmaceutical manufacturing sites to support molecular and nuclear imaging facilities on the continent that are gearing up to perform scientific studies for the program.
Established in October 2008, the network aims at streamlining drug discovery and development through commercially sponsored, multicenter clinical trials and advanced radiopharmaceutical and biomarkers technologies.
The SNM has developed trial protocols and is beginning to conduct clinical site education, and equipment testing using PET scanner phantoms, designed specifically for the network, to assure consistent site-to-site performance for multicenter pharmaceutical trials run by drug companies that contract for the society's services.
According to the SNM, 217 imaging sites in the U.S., 28 in Europe, and 22 elsewhere in the world have registered for the network.
The SNM announced July 23 that three European radiopharmacy companies have registered their 27 radiopharmaceutical manufacturing sites with the network. They are Advanced Accelerator Applications, Erigal Limited, and IBA Molecular.
Their participation will afford European clinical trial sites the option to obtain investigational imaging agents, such as fluorine-18 3'-deoxy-3'-fluorothymidine (FLT), from a commercial provider instead of having to produce it themselves, said Dr. Michael M. Graham, SNM president and trial network cochair.
The society had intended from its inception to include European sites in the network, Graham said.
"European institutions have an extensive history in clinical trials experience and they bring critical knowledge and capability to the network registries," he said.
The network has also lined up radiopharmacies in the U.S. to supply radiopharmaceuticals to trial sites in this country. In June, PETNet Solutions, Cardinal Health, and IBA Molecular all provided the SNM with access to FDA drug master files for FLT. F-18 FLT PET shows promise for monitoring responses to therapy by noninvasively measuring cell proliferation.
SNM's Clinical Trials Network received investigational new drug status from the FDA for the use of FLT in multicenter studies. Each imaging site that participates in a study will use the society's multicenter IND approval when FLT is employed in its assigned clinical trial.
But instead of having to submit detailed information about in-house production methods, sites will have the option to purchase investigational biomarkers from one of the commercial manufacturers that has provided access to its FDA drug master file to the SNM.
"We hope that having commercial PET radiopharmaceutical producers supply investigational agents will further improve the level of standardization in imaging biomarker production," Graham said. "But this in no way reduces the need for single-site-produced biomarkers. We need both."
The network's success ultimately depends on partnerships with pharmaceutical companies to perform multicenter drug trials through the network. In March, Genentech, a pioneer biotech company in South San Francisco, CA, became the first pharmaceutical concern to contract for the networks' services.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.